Dược Lực Học :
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. It is therefore indicated for ovarian cancer.
Cơ Chế Tác Dụng :
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells. Antiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor are suited to this approach.
To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported.
To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. ACA 125 (Ab2) showed high affinity for the paratope of Abl. Binding of Ab2 to Abl is completely inhibited by the nominal antigen. Application of fragments of ACA 125 to rats lead to an anti-CA 125 immunity by production of IgG and IgM antiantiidiotypic antibodies (Ab3) that bind to both ACA 125 and CA 125.
Chỉ Định :
Investigated for use/treatment in ovarian cancer.